Business Context and Reporting Period
Company: Bausch + Lomb Corporation (BLCO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A leading global eye health company operating in three segments: Vision Care (contact lenses, OTC eye care), Pharmaceuticals (prescription eye medications), and Surgical (medical devices, IOLs). The Company is currently a subsidiary of Bausch Health Companies Inc. (BHC), which holds approximately 88% of outstanding shares, with a planned separation pending.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | 6M 2025 | 6M 2024 |
|---|---|---|---|---|
| Total Revenues | $1,278 | $1,216 | $2,415 | $2,315 |
| Operating (Loss) Income | $(11) | $26 | $(94) | $32 |
| Net Loss (Attributable to B+L) | $(62) | $(151) | $(274) | $(318) |
| Diluted Loss Per Share | $(0.18) | $(0.43) | $(0.78) | $(0.90) |
| Operating Cash Flow (6M) | $10 | $56 | - | - |
| Total Debt (Principal) | $5,024 | - | - | - |
| Cash & Equivalents | $266 | - | - | - |
Note: Q2 2024 and 6M 2024 debt/cash figures are not explicitly provided in the summary text for direct comparison, though 6M 2024 operating cash flow was $56 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% ($62 million) in Q2 2025 and 4% ($100 million) for the six months ended June 30, 2025, compared to the prior year periods. Growth was driven by increased volumes in Vision Care and Pharmaceuticals, favorable foreign currency impacts, and incremental sales from acquisitions.
- Profitability Decline: Operating income turned negative in Q2 2025 ($(11) million) compared to $26 million in Q2 2024. For the six months, operating loss widened to $(94) million from operating income of $32 million in the prior year. This was primarily due to increased Selling, General, and Administrative (SG&A) expenses and higher interest costs.
- Segment Performance:
- Vision Care: Revenue increased 8% (Q2) and 6% (6M), driven by dry eye portfolio and contact lens sales.
- Pharmaceuticals: Revenue remained flat (Q2) and declined slightly (6M) due to pricing pressures and declines in U.S. generics, partially offset by MIEBO growth.
- Surgical: Revenue increased 3% (Q2) and 6% (6M), driven by consumables and acquisitions, though impacted by the enVista IOL recall.
- Debt Refinancing: In June 2025, the Company refinanced its debt structure, entering into a new $800 million revolving credit facility and a $2.325 billion term loan facility, while repaying prior 2027 maturities. This resulted in a $9 million loss on extinguishment of debt.
Guidance, Outlook, Risks, and Unusual Items
- Voluntary Recall: In March 2025, the Company voluntarily recalled certain enVista IOL products due to reports of toxic anterior segment syndrome (TASS). The issue was traced to raw materials from a specific vendor. Production has resumed with enhanced inspection protocols, but the recall impacted Surgical segment profitability and contributed to inventory reserves.
- Acquisitions: The Company acquired Whitecap Biosciences (Jan 2025), Elios Vision (Dec 2024), and Trukera Medical (July 2024). These acquisitions added to R&D expenses and goodwill but are expected to bolster the glaucoma and dry eye portfolios.
- Separation from BHC: The Company remains a subsidiary of BHC. A full separation (via distribution or sale) is planned but contingent on achieving targeted debt leverage ratios and regulatory approvals. No assurance is given that the separation will occur or on its timeline.
- Legal Proceedings: Significant ongoing litigation includes antitrust claims regarding generic pricing (shared with BHC), product liability suits related to Shower to Shower (indemnified by Johnson & Johnson), and patent infringement disputes regarding Lumify (settled with DRL for market entry in 2027).
- Macroeconomic Risks: The Company faces risks from U.S. tariffs, trade restrictions, and geopolitical conflicts (Russia-Ukraine, Middle East), which could impact supply chains and costs. The "One Big Beautiful Bill Act" (signed July 2025) may impact future tax provisions.
- Guidance: The filing does not provide specific numerical financial guidance for the full year 2025. Management expects to remain in compliance with financial covenants over the next 12 months.
Key Facts for Investor Verification
- Debt Covenants: Verify the Company's ability to maintain the maximum first lien net leverage ratio (currently capped at 5.75:1.00) required by the new June 2030 Revolving Credit Facility.
- enVista Recall Impact: Monitor the long-term financial impact of the enVista IOL recall on the Surgical segment's revenue and the success of the resupply efforts.
- Separation Timeline: Track progress on the separation from BHC, specifically the achievement of debt leverage targets and regulatory approvals, as this is a critical strategic milestone.
- Patent Expirations: Assess the impact of upcoming generic competition for key products like Lumify and PreserVision, despite recent settlements extending exclusivity for some competitors.
- Interest Rate Exposure: Evaluate the impact of the weighted average interest rate of 8.06% on future earnings, particularly given the significant refinancing activity in Q2 2025.